PeptideHub
Home
Peptides
CalculatorProtocolsSchedule
HomePeptidesCalculatorProtocolsSchedule
Back to Encyclopedia
Healing & RecoveryFDA ApprovedIntermediate

Pentosan Polysulfate (PPS)

Pentosan Polysulfate Sodium

Also known as: PPS, Elmiron, Cartrophen, NaPPS

Overview

A semi-synthetic polysulfated xylan derived from beechwood hemicellulose. FDA-approved for interstitial cystitis and widely used in veterinary medicine for osteoarthritis. Promotes joint recovery and cartilage protection.

Half-Life
~20 hours (oral)
Typical Dose
100–300 mg
Frequency
Oral: 3x daily; Injectable: 1x weekly
Cycle Length
8-16 weeks minimum

Administration

OralSubcutaneousIntramuscular

Benefits

  • Protects and rebuilds cartilage matrix
  • Reduces joint inflammation and pain
  • Improves synovial fluid quality
  • Anti-thrombotic and fibrinolytic properties
  • Protects bladder lining (interstitial cystitis)
  • Stimulates proteoglycan synthesis in joints

Side Effects

  • GI discomfort (nausea, diarrhea)
  • Headache
  • Mild hair thinning (reversible, rare)
  • Bruising or bleeding tendency at higher doses
  • Maculopathy with long-term high-dose use (FDA warning)

Mechanism of Action

  • Inhibits degradative enzymes (hyaluronidase, elastase) in cartilage
  • Stimulates chondrocyte proteoglycan and collagen synthesis
  • Restores glycosaminoglycan layer on bladder/joint surfaces
  • Weak anticoagulant activity through antithrombin III
  • Reduces inflammatory mediator release in synovial tissue

Contraindications

  • Active bleeding or hemophilia
  • Concurrent anticoagulant therapy (increased bleeding risk)
  • Hepatic insufficiency
  • Pregnancy or breastfeeding
  • Pre-existing macular disease (requires ophthalmologic monitoring)

Storage & Reconstitution

Store oral capsules at room temperature (15–25°C (59–77°F)). Injectable formulation: store at 2–8°C (36–46°F). Do not freeze.

Common peptide amounts:10 mg

Research Summary

FDA-approved as Elmiron for interstitial cystitis since 1996. Extensive veterinary use (Cartrophen Vet) for osteoarthritis in dogs and horses with strong efficacy data. Post-marketing surveillance identified rare maculopathy risk with prolonged use prompting FDA label update in 2020.

Commonly Stacked With

Healing & RecoveryBPC-157
Healing & RecoveryGHK-Cu

This information is for educational purposes only. Always consult a qualified healthcare professional before using any peptide.